Current Urology Reports

, Volume 10, Issue 4, pp 307–312 | Cite as

Phenotypic approach to the Management of chronic prostatitis/chronic pelvic pain syndrome

Article

Abstract

There is no one unifying etiological mechanism or specific curative therapy for chronic prostatitis/ chronic pelvic pain syndrome (CP/CPPS). However, there is sufficient evidence to suggest that each of the proposed mechanisms may be important in some patients, and that many of our evaluated treatments do in fact work in subgroups of patients. We hypothesize that CP/CPPS patients are not a homogenous group suffering from a single disease entity. Rather, CP/CPPS patients are actually unique individuals with differing clinical phenotypes based on various etiological mechanisms with distinctive symptom complexes and progression trajectories. We call this the “Snow Flake Hypothesis.” We propose the UPOINT (urinary, psychosocial, organ-specific, infection, neurologic/systemic, and tenderness domains) clinical phenotyping classification; we have validated the concept in a CP/CPPS cohort and have suggested that phenotypically directed therapy will improve our clinical treatment outcomes.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    McNaughton-Collins M, Joyce GF, Wise M, et al.: Prostatitis. In Urologic Diseases in America. Edited by Litwin MS, Saigal CS. US Dept of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington DC: US Government Printing Office; 2007:9–41.Google Scholar
  2. 2.
    Calhoun EA, McNaughton-Collins M, Pontari MA, et al.: The economic impact of chronic prostatitis. Arch Intern Med 2004, 164:1231–1236.PubMedCrossRefGoogle Scholar
  3. 3.
    McNaughton-Collins M, Pontari MA, O’Leary MP, et al.: Quality of life is impaired in men with chronic prostatitis: the Chronic Prostatitis Collaborative Research Network. J Gen Intern Med 2001, 16:656–662.PubMedCrossRefGoogle Scholar
  4. 4.
    Shoskes DA, Nickel JC, Rackley RR, Pontari MA: Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromes. Prostate Cancer Prostatic Dis 2009 (in press).Google Scholar
  5. 5.
    Shoskes DA, Nickel JC, Dolinga R, Prots D: Clinical phenotyping of chronic prostatitis/chronic pelvic pain patients and correlation with symptom severity. Urology 2009, 73:538–543.PubMedCrossRefGoogle Scholar
  6. 6.
    Nickel JC: Inflammatory conditions of the male genitourinary tract: prostatitis and related conditions, orchitis, and epididymitis. In Campbell-Walsh Urology, edn 9. Edited by Wein AJ, Kavoussi LR, Novick AC, et al. Philadelphia: Elsevier; 2006:330–370.Google Scholar
  7. 7.
    Krieger JN, Nyberg L Jr, Nickel JC: NIH consensus definition and classification of prostatitis. JAMA 1999, 282:236–237.PubMedCrossRefGoogle Scholar
  8. 8.
    Nickel JC, Nyberg L, Hennenfent M: Research guidelines for chronic prostatitis: a consensus report from the First National Institutes of Health-International Prostatitis Collaborative Network (NIH-IPCN). Urology 1999, 54:229–233.PubMedCrossRefGoogle Scholar
  9. 9.
    Litwin MS, McNaughton-Collins M, Fowler FJ Jr, et al.: The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. J Urol 1999, 162:369–375.PubMedCrossRefGoogle Scholar
  10. 10.
    Nickel JC, Downey J, Clark J, et al.: Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial. Urology 2003, 62:614–617.PubMedCrossRefGoogle Scholar
  11. 11.
    Alexander RB, Propert KJ, Schaeffer AJ, et al.: Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome. Ann Intern Med 2004, 141:581–589.PubMedGoogle Scholar
  12. 12.
    Nickel JC, Pontari M, Moon T, et al.: A randomized, placebo-controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. J Urol 2003, 169:1401–1405.PubMedCrossRefGoogle Scholar
  13. 13.
    Nickel JC, Krieger JN, McNaughton-Collins M, et al.: Effect of alfuzosin on symptoms in men with chronic prostatitis/ chronic pelvic pain syndrome. N Engl J Med 2009 (in press).Google Scholar
  14. 14.
    Nickel JC, Downey J, Pontari MA, et al.: Randomized placebo-controlled, multi-center study to evaluate the safety and efficacy of finasteride in the treatment of male chronic pelvic pain syndrome: category IIIA CPPS (chronic nonbacterial prostatitis). BJU Int 2004, 93:991–995.PubMedCrossRefGoogle Scholar
  15. 15.
    Nickel JC, Forrest JB, Tomera K, et al.: Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo-controlled study. J Urol 2005, 173:1252–1255.PubMedCrossRefGoogle Scholar
  16. 16.
    Pontari MA, Krieger J, Litwin MS, et al.: A randomized placebo-controlled multicenter trial of pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome [abstract 340]. J Urol 2009, 181(Suppl 4):123.CrossRefGoogle Scholar
  17. 17.
    Nickel JC, Xiang J: Clinical significance of non-traditional uropathogens in the management of chronic prostatitis. J Urol 2008, 179:1391–1395.PubMedCrossRefGoogle Scholar
  18. 18.
    Cheah PY, Liong ML, Yuen KH, et al.: Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. J Urol 2003, 169:592–596.PubMedCrossRefGoogle Scholar
  19. 19.
    Mehik A, Alas P, Nickel JC, et al.: Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study. Urol 2003, 62:425–429.PubMedCrossRefGoogle Scholar
  20. 20.
    Tugcu V, Tasci AI, Fazlioglu A, et al.: A placebo-controlled comparison of the efficiency of triple- and monotherapy in category III B chronic pelvic pain syndrome (CPPS). Eur Urol 2007, 51:1113–1118.PubMedCrossRefGoogle Scholar
  21. 21.
    Nickel JC, Narayan P, McKay J, Doyle C: Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double-blind trial. J Urol 2004, 171:1594–1597.PubMedCrossRefGoogle Scholar
  22. 22.
    Yang G, Wei Q, Li H, et al.: The effect of alpha-adrenergic antagonists in chronic prostatitis/chronic pelvic pain syndrome: a meta-analysis of randomized controlled trials. J Androl 2006, 27:847–852.PubMedCrossRefGoogle Scholar
  23. 23.
    Mishra VC, Browne J, Emberton M: Role of alpha-blockers in type iii prostatitis: a systemic review of the literature. J Urol 2007, 177:25–30.PubMedCrossRefGoogle Scholar
  24. 24.
    Nickel JC, Shoskes D, Irvine-Bird K: Clinical phenotyping of women with interstitial cystitis/painful bladder syndrome (IC/PBS): a key to classification and potentially improved management. J Urol 2009 (in press).Google Scholar
  25. 25.
    Nickel JC, Downey J, Ardern D, et al.: Failure of a monotherapy strategy for difficult chronic prostatitis/chronic pelvic pain syndrome. J Urol 2004, 172:551–554.PubMedCrossRefGoogle Scholar
  26. 26.
    Shoskes DA, Hakim L, Ghoniem G, Jackson CL: Long-term results of multimodal therapy for chronic prostatitis/ chronic pelvic pain syndrome. J Urol 2003, 169:1406–1410.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.Department of UrologyQueen’s University, Kingston General HospitalKingstonCanada

Personalised recommendations